Clinical Trial Update: Efficacy and Safety of Grass Pollen Sublingual Immunotherapy [Phase 2, Phase 3]

View source ↗

Summary

This clinical trial update evaluates the efficacy and safety of Grass pollen sublingual immunotherapy for allergic rhinoconjunctivitis in Phase 2 and Phase 3 st…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Rhinoconjunctivitis

Drugs mentioned

• Grass pollen sublingual immunotherapy

Snippet

Sponsor: Artu Biologicals | Conditions: Allergic Rhinoconjunctivitis | Phase 2, Phase 3 | Status: COMPLETED